Form 4: Director Michael Singer Boosts Cartesian Therapeutics Stake

Cartesian Therapeutics Director Michael Singer reported acquiring 2,600 restricted stock units and 7,800 stock options, increasing his beneficial ownership.

Summary

• Michael Singer, a Director and 10% Owner of Cartesian Therapeutics, Inc. (RNAC), reported an acquisition of securities.
• On January 2, 2026, Singer acquired 2,600 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0 per share.
• These RSUs represent a contingent right to receive one share of common stock each and will vest in full on January 2, 2027.
• Additionally, on January 2, 2026, Singer acquired 7,800 Stock Options (Right to Buy) at a price of $0, with an exercise price of $6.76 per share.
• These stock options become exercisable on January 2, 2027, and have an expiration date of January 1, 2036.
• Following these transactions, Singer directly beneficially owns 56,133 shares of Common Stock and 7,800 Stock Options.
• Indirect beneficial ownership includes 383,796 shares held by a trust for his spouse and children, 56,719 shares by a trust where he is a beneficiary and trustee, 7,127 shares by a trust where he is a beneficiary and his spouse is a trustee, 14,788 shares by his spouse, and 96,219 shares each in two separate custodial accounts for his children (LS and SS) under UTMA, for which he serves as custodian.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The acquisition of equity by a director and 10% owner, even if compensation, generally signals alignment of interests and potential confidence in the company's future performance. There are no negative aspects reported in this filing.

Positives

• Director Michael Singer's acquisition of 2,600 Restricted Stock Units and 7,800 Stock Options aligns his interests with those of shareholders, signaling confidence in the company's future.
• The increase in beneficial ownership by a significant insider (Director and 10% Owner) can be viewed as a positive indicator for the company's prospects.

Related Party Transactions

• Indirect beneficial ownership includes shares held in trusts for the benefit of the reporting person's spouse and children, shares held by the reporting person's spouse, and shares held in custodial accounts for the reporting person's children, all of which are standard disclosures for related party holdings in a Form 4.

Stakeholder Impact

• Shareholders: The acquisition of additional equity by a director and 10% owner can be seen as a positive signal, potentially increasing investor confidence due to greater alignment of management's interests with shareholder value.
• Management/Employees: The equity awards serve as an incentive, aligning the director's long-term financial interests with the company's performance.

Next Steps

• The 2,600 Restricted Stock Units are scheduled to vest in full on January 2, 2027.
• The 7,800 Stock Options will become exercisable on January 2, 2027, and can be exercised until their expiration on January 1, 2036.

Key Dates

Recommendation

The acquisition of restricted stock units and stock options by a director and 10% owner, while likely part of a compensation package, generally indicates alignment of interests and a degree of confidence in the company's future. This insider activity provides a positive signal, suggesting that the director believes in the long-term value of the company. However, without further financial or operational details, it primarily reinforces a 'hold' position for existing investors and warrants further due diligence for potential new investors, as it's not an open market purchase.

Keywords

Cartesian Therapeutics, RNAC, Michael Singer, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Beneficial Ownership, Director Ownership, Equity Compensation